KemPharm uses its LAT
platform technology to discover and develop prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety.
KMPH (Common Stock)
12/12/17 3:55 p.m. ET
KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update
KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.
View Attributions and Sources